Homocysteinelevelsareassociated withtheseverityofperipheral arterial disease in type 2 diabetic patients

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 12, 2003, Pages 2540-2547

  Ciccarone, E ^a,b   Di Castelnuovo, A ^a   Assanelli, D ^b   Archetti, S ^c   Ruggeri, G ^c   Salcuni, N ^d   Donati, M B ^e   Capani, F ^b   Iacoviello, L ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d SPEDALI CIVILI   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

Homocysteine; MTHFR polymorphism; Peripheral arterial disease; Type 2 diabetes

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PYRIDOXINE;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; GENETICS; HUMAN; ITALY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; ROC CURVE;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; ITALY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; ROC CURVE; VITAMIN B 6;

EID: 1542440251     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2003.00500.x     Document Type: Article

References (42)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-8.
2. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
4. HomocysteineStudiesCollaboration. Homocysteineandrisk ofischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22.
5. Malinow MR. Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. J Nutr 1996; 126: 1238S-43S.
6. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
7. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arter-ioscler Thromb Vasc Biol 1998; 18: 133-8.
8. Kang SS, Wong PW, Zhou JM, Sora J, Lessick M, Ruggie N, Grcevich G. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988; 37: 611-3.
9. Kluijtmans LA, Kastelein JJ, Lindemans J, Boers GH, Heil SG, Bruschke AV, Jukema JW, van den Heuvel LP, Trijbels FJ, Boerma GJ, Verheugt FW, Willems F, Blom HJ. Thermolabile methylenetetra-hydrofolate reductase in coronary artery disease. Circulation 1997; 96: 2573-7.
10. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032-6.
11. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosen-blatt DS, Genest J Jr, Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 569-73.
12. Verhoef P, Kok FJ, Kluijtmans LA, Blom HJ, Refsum H, Ueland PM, Kruyssen DA. The 677C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 132: 105-13.
13. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WT Jr, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methy-lenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-7.
14. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate re-ductase polymorphism, plasma folate, homocysteine, and risk of myo-cardial infarction in US physicians. Circulation 1996; 94: 2410-6.
15. Second European Consensus Document on chronic critical leg ischemia. Circulation 1991; 84: IV1-26.
16. Langholz J. Investigation of peripheral arterial disease-the expanding role of echo-enhanced color flow doppler and duplex sonography. Eur J Ultrasound 1998; 7 (Suppl. 3): S53-61.
17. Zighetti ML, Cattaneo M, Falcon CR, Lombardi R, Harari S, Savoritto S, Mannucci PM. Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension. Thromb Res 1997; 85: 279-82.
18. WHO MONICA Project. MONICA Manual. 1998-1999. Available from URL http://www.ktl.fi/publications/monica/manual/index.htm
19. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
20. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Arch Intern Med 1998; 158: 1301-6.
21. Drzewoski J, Czupryniak L, Chwatko G, Bald E. Hyperhomocysteine-mia in poorly controlled type 2 diabetes patients. Diabetes Nutr Metab 2000; 13: 319-24.
22. Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS, Dobs A, Evans GW, Heiss G. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997; 131: 115-25.
23. Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999; 29: 8-21.
24. Rassoul F, Richter V, Janke C, Purschwitz K, Klotzer B, Geisel J, Herrmann W. Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology 2000; 51: 189-96.
25. Aronow WS, Ahn C. Association between plasma homocysteine and peri-pheralarterialdisease inolderpersons. Coron Artery Dis 1998; 9: 49-50.
26. Hoogeveen EK, Kostense PJ, Jakobs C, Rauwerda JA, Dekker JM, Nijpels G, Bouter LM, Heine RJ, Stehouwer CD. Hyperhomocystei-nemia is not associated with isolated arterial occlusive disease: The Hoorn Study. J Intern Med 2000; 247: 442-8.
27. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homo-cysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.
28. Bloemenkamp DG, van den Bosch MA, Mali WP, Tanis BC, Rosendaal FR, Kemmeren JM, Algra A, Visseren FL, van der Graaf Y. Novel risk factors for peripheral arterial disease in young women. Am J Med 2002; 15: 462-7.
29. Kneth P, Reunanen A, Alfthan G, Heliovaara M, Rissanen H, Marniemi J, Aromaa A. Hyperhomocysteinemia. Arch Int Med 2001; 161: 1589-94.
30. Cattaneo M. Hyperhomocysteinemia and atherothrombosis. Ann Med 2000; 32 (Suppl. 1): 46-52.
31. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76.
32. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506-11.
33. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 55: 1028-35.
34. Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh P, Fulcher GR. The relationship among homocysteine, creatinine clear-ance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001; 24: 1805-9.
35. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-depen-dent diabetic patients with and without albuminuria. Kidney Int 1999; 55: 308-14.
36. Mazza A, Motti C, Nulli A, Marra G, Gnasso A, Pastore A, Federici G, Cortese C. Lack of association between carotid intima-media thickness and methylenetetrahydrofolate reductase gene polymorphism or serum homocysteine in non-insulin-dependent diabetes mellitus. Metabolism 2000; 49: 718-23.
37. Kaye JM, Stanton KG, McCann VJ, Vasikaran SD, Burke V, Taylor RR, van Bockxmeer FM. Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clin Sci (Lond) 2002; 102: 631-7.
38. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, Faccini G, Pignatti PF, Mazzucco A, Corrocher R. Methylenetetra-hydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographi-cally documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998; 91: 4158-63.
39. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023-31.
40. Scaglione L, Gambino R, Rolfo E, Lillaz E, Gai M, Cassader M, Pagano G, Cavallo-Perin P. Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002; 32: 24-8.
41. Pepe G, Camacho Vanegas O, Giusti B, Brunelli T, Marcucci R, Attanasio M, Rickards O, De Stefano GF, Prisco D, Gensini GF, Abbate R. Heterogeneity in world distribution of the thermolabile C677T mutation in 5,10-methylenetetrahydrofolate reductase. Am J Hum Genet 1998; 63: 917-20.
42. Abbate R, Sardi I, Pepe G, Marcucci R, Brunelli T, Prisco D, Fatini C, Capanni M, Simonetti I, Gensini GF. The high prevalence of thermo-labile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost 1998; 79: 727-30.